IF: 0.644
REUTERS THOMSON

Comparison of Oral and Intravenous Proton Pump Inhibitor on Patients with High Risk Bleeding Peptic Ulcers: A Prospective, Randomized, Controlled Clinical Trial

AUTHORS

AA Mostaghni 1 , SA Hashemi 2 , * , ST Heydari 1

AUTHORS INFORMATION

1 Division of Gastroenterology and Hepatology, Shiraz University of Medical Sciences, Fars, Iran

2 MD, Shiraz, Fars

How to Cite: Mostaghni A, Hashemi S, Heydari S. Comparison of Oral and Intravenous Proton Pump Inhibitor on Patients with High Risk Bleeding Peptic Ulcers: A Prospective, Randomized, Controlled Clinical Trial , Iran Red Crescent Med J. Online ahead of Print ; 13(7):458-463.

ARTICLE INFORMATION

Iranian Red Crescent Medical Journal: 13 (7); 458-463
Article Type: Research Article
Received: November 10, 2011
Accepted: February 12, 2011

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: Proton pump inhibitors (PPIs) decrease the rate of rebleeding following endoscopic hemostatic therapy in patients with bleeding peptic ulcers. This study compares the efficacy of oral omeprazole vs intravenous pantoprazole in decrease of rebleeding of peptic ulcer patients.

Methods: One hundred and six patients with high risk peptic ulcer were randomized to receive either oral omeprazole (80 mg BID for 3 days) or IV pantoprazole (80 mg bolus and 8 mg/hour infusion for 3 days) followed by omeprazole (20 mg each day for 30 days). All patients underwent upper endoscopy and endoscopic therapy within 24 hours.

Results: Seventeen patients were excluded from the study. Forty four patients were randomly allocated into omeprazole group and 41 patients to IV pantoprazole group. Both groups were similar for factors affecting the outcome. Bleeding reoccurred in five patients of omeprazole group and four patients in pantoprazole group (11.4% vs 9.8 %). The mean hospital stay and blood transfusion were not different in both groups.

Conclusion: Oral omeprazole and IV pantoprazole had equal effects on prevention of rebleeding after endoscopic therapy in patients with high risk bleeding peptic ulcers.

Keywords

Proton pump inhibitor Bleeding Peptic ulce

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: